Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin

University Hospital, Montpellier17 enrolled

Overview

Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital

Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the department of MPR on the criteria of judgment, then the patient is admitted in a service of neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service for post-treatment evaluation. Collection of data retrospectively.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Post-Poliomyélitis Syndrom

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of PPS * Pre- and post-therapeutic evaluation carried out * Data transcribed in the computerized patient file Exclusion Criteria: * No walking patient

Locations (1)

Uh Montpellier

Montpellier, France

Outcomes

Primary Outcomes

Muscular strength

Muscular strength with isokinetic

Time frame: 5 months

Secondary Outcomes

Walking perimeter

Walking perimeter with walking test (6 minutes)

Time frame: 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.